Scholar Rock

SRRK · Nasdaq · United States

Share price · SRRK

$48.00-6.72 (-12.28%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.8M (1.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SRRK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+6.5%
  2. 10 Nov 2026-6.9%
  3. 9 Nov 2026+9.8%
  4. 5 Oct 2026-7.3%
  5. 14 Sep 2026-6.4%
  6. 8 Sep 2026+3.8%

    Nothing announced by SRRK that day or the session before.

  7. 18 Aug 2026+5.1%

    Nothing announced by SRRK that day or the session before.

  8. 6 Aug 2026+10.0%
  9. 31 Mar 2026+14.1%
  10. 19 Mar 2026+14.4%

Share of unusual movement by asset

For each asset, the share of SRRK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
apitegromab (Isembyld)
events and moves
1795%
Other company news (earnings, financing, releases naming no asset)—2%
Sessions with no dated event—3%

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
apitegromab(Isembyld)
Approved
Myostatin (pro/latent form)Monoclonal antibody
ObesitySpinal Muscular Atrophy

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
June 2028 (1)
apitegromab · IsembyldPhase 2Facioscapulohumeral Muscular Dystrophy, FSHD
Est. primary completion 2028-06 · NCT07435129 · CT.gov ↗
What to watch
November 2028 (1)
apitegromab · IsembyldPhase 2Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3, Neuromuscular Manifestations, Anti-myostatin
Est. primary completion 2028-11 · NCT07047144 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(10)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 October 2026Filing submittedapitegromabApitegromab MAA resubmitted to the EMA
EU, EMA · Scholar Rock · Source ↗
11 September 2026ApprovalapitegromabFDA approves apitegromab as ISEMBYLD
US, FDA · Scholar Rock · Source ↗
August 2026WithdrawalapitegromabPrevious apitegromab MAA withdrawn
EU, EMA · Scholar Rock · Source ↗
31 March 2026Filing submittedapitegromabApitegromab BLA resubmitted to FDA
US, FDA · Source ↗
23 September 2025Complete response letterapitegromabFDA issues a complete response letter for the apitegromab BLA
US, FDA · Scholar Rock · Source ↗
22 September 2025FDA action dateapitegromabPDUFA target date set for September 22, 2025
US, FDA · Source ↗
September 2025Complete response letterapitegromabFDA issued complete response letter
US, FDA · Source ↗
25 March 2025Filing acceptedapitegromabFDA accepts apitegromab BLA
US, FDA · Source ↗
25 March 2025Priority reviewapitegromabFDA grants priority review for apitegromab BLA
US, FDA · Source ↗
29 January 2025Filing submittedapitegromabBLA submitted to FDA for apitegromab in SMA
US, FDA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$54M$370M+ $47M short-term inv.$107M-$82M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$58M$441M+ $55M short-term inv.$110M-$70M operating cash flowreport ↗
2026-Q1$0$52M$434M+ $49M short-term inv.$106M-$82M operating cash flowreport ↗
2025-Q3—$50M$291M+ $83M short-term inv.$102M-$69M operating cash flowreport ↗
2025-Q2—$62M$155M+ $142M short-term inv.$110M-$77M operating cash flowreport ↗
2025-Q1—$49M$140M+ $226M short-term inv.$75M-$79M operating cash flowreport ↗
2024-Q3—$49M$79M+ $63M short-term inv.$64M-$52M operating cash flowreport ↗
2024-Q2—$42M$96M+ $97M short-term inv.$59M-$49M operating cash flowreport ↗
2024-Q1—$43M$94M+ $146M short-term inv.$57M-$50M operating cash flowreport ↗
2023-Q3—$30M$70M+ $151M short-term inv.$42M-$32M operating cash flowreport ↗
2023-Q2—$27M$111M+ $141M short-term inv.$38M-$33M operating cash flowreport ↗
2023-Q1—$30M$154M+ $124M short-term inv.$39M-$43M operating cash flowreport ↗
2022-Q3—$33M$136M+ $211M short-term inv.$43M-$26M operating cash flowreport ↗
2022-Q2—$32M$308M+ $65M short-term inv.$44M-$35M operating cash flowreport ↗
2022-Q1$33M$29M$103M+ $110M short-term inv.$8.0M-$43M operating cash flowreport ↗
2021-Q3$5.5M$31M$179M+ $70M short-term inv.$38M-$36M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$208M$327M+ $44M short-term inv.$94M-$300M operating cash flowreport ↗

Scholar Rock recorded no revenue in 2025 or 2024, with R&D expense of $208.44M, up 12.9% YoY. Cash and equivalents were $327.33M, while cash, cash equivalents, and marketable securities were $367.6M at year-end. The full-year net loss was $377.94M, including a Q4 net loss of $91.0M.

The company expects to resubmit the apitegromab BLA and launch in the U.S. in 2026 following a successful FDA reinspection of Catalent Indiana; the recent FDA meeting was constructive, with no additional corrective actions requested. The EMA decision on the apitegromab MAA is expected in mid-2026, with European launch planned for H2 2026 beginning in Germany. A new debt facility provides up to $550M in non-dilutive capital. Other milestones include Phase 2 FORGE initiation in FSHD in mid-2026, ongoing Phase 2 OPAL enrollment, SRK-439 Phase 1 topline data in H2 2026, and a supplemental BLA for a second fill-finish facility later in 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$185M$180M+ $259M short-term inv.$62M-$201M operating cash flowreport ↗
2023-FY—$122M$104M+ $178M short-term inv.$41M-$145M operating cash flowreport ↗
2022-FY$33M$124M$106M+ $212M short-term inv.$34M-$133M operating cash flowreport ↗
2021-FY$19M$108M$215M+ $40M short-term inv.$33M-$127M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 6 purchases ($12.0M), 38 sales ($19.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-26AKKARAJU SRINIVAS · directorOpen-market purchase48,988$41.59$2.0MForm 4
2026-10-26AKKARAJU SRINIVAS · directorOpen-market purchase97,982$41.59$4.1MForm 4
2026-10-23AKKARAJU SRINIVAS · directorOpen-market purchase47,000$41.31$1.9MForm 4
2026-10-23AKKARAJU SRINIVAS · directorOpen-market purchase94,000$41.31$3.9MForm 4
2026-10-23AKKARAJU SRINIVAS · directorOpen-market purchase500$41.82$21KForm 4
2026-10-23AKKARAJU SRINIVAS · directorOpen-market purchase1,000$41.82$42KForm 4
2026-09-24Woods Keith · Chief Operating OfficerGift48,034——Form 4
2026-09-21Hallal David · director, Chief Executive OfficerGift36,652——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 272 reporting institutions held 133.8M shares ($6.3B, 109.7% of shares outstanding).

#InstitutionSharesValue
1FMR LLC17,243,152$847.7M
2Siren, L.L.C.10,825,013$532.2M
3Redmile Group, LLC9,066,621$445.7M
4BlackRock, Inc.7,469,293$367.2M
5SAMSARA BIOCAPITAL, LLC6,897,652$339.1M
6WELLINGTON MANAGEMENT GROUP LLP6,717,655$330.2M
7Orbis Allan Gray Ltd4,179,983$205.5M
8STATE STREET CORP4,031,317$198.2M
9VANGUARD CAPITAL MANAGEMENT LLC3,891,347$191.3M
10Bellevue Group AG3,584,573$176.2M
11JENNISON ASSOCIATES LLC3,340,492$164.2M
12JANUS HENDERSON GROUP PLC2,236,837$109.9M
13EVENTIDE ASSET MANAGEMENT, LLC2,197,385$107.9M
14GEODE CAPITAL MANAGEMENT, LLC2,149,036$105.7M
15STEMPOINT CAPITAL LP2,070,992$101.8M